Troy Piccinini

@AmandaBoersen I’m invested long term but also trading in a side account so always love someone else analysis and thoughts. Appreciate it. Could you says this was just a “gap” close and short term profit taking before moving up again or no?

Valid point. A $1.93 close vs a $1.95 pivot shows the tape is currently lacking the aggressive delta needed to clear the overhead supply cluster immediately. However, professional trading is about 'confirmation' rather than 'anticipation.' We are currently in a high-volatility consolidation zone. While $1.55 remains the macro objective if the $1.80 structural floor fails on volume, the immediate focus is whether the $1.93 level acts as a 'bear trap' or a 'lower high' rejection. I am monitoring the 1-hour order flow for signs of institutional absorption. I’ll be updating the precise invalidation triggers and the 'buy-zone' adjustments in my private strategy group—feel free to check the link in bio for the real-time plan.

$OCGN | Today’s clinical data release is the "make-or-break" moment the market has been pricing in. While the 12-month Phase 2 ArMaDa trial results for OCU410 are fundamentally a "best-in-class" signal—boasting a 31% reduction in lesion growth—the 4-hour technical tape is currently delivering a high-stakes warning to anyone blindly chasing the headline. The objective data on the chart is surgical. $OCGN is currently testing the critical lower boundary of its macro ascending channel. We have successfully defended the $1.80 structural floor, but we are now staring directly at a heavy resistance cluster near $1.95 - $2.10. Our momentum oscillator is sitting at a neutral 50.06, suggesting the initial "data pump" euphoria is being met by institutional supply. The Fundamental Conflict: Breakthrough vs. Execution The Bull Case: With OCU400 Phase 3 enrollment complete and a rolling BLA targeted for Q3 2026, Ocugen is no longer a "COVID-pivot" story; it is a legitimate gene-therapy contender. The OCU410 data potentially positions it as a superior, one-time treatment for geographic atrophy compared to existing billion-dollar multi-injection therapies. The Bear Case: The market is ruthlessly focused on the cash runway. Despite the January financing, the burn rate for three late-stage programs is intense. At $1.92, the stock is at a technical inflection point where failure to break $2.10 could trigger a "sell the news" liquidation back toward the $1.55 support. Technical Structure: We are tracking a potential Wave (3) extension toward the channel's upper rail at $2.60+, but only if the daily close sustains above the $1.95 pivot. Chasing here without a confirmed volume breakout is a recipe for being trapped in a "wick rejection." If you are currently holding $OCGN from the $2.00+ rejections or looking to tactical play this clinical catalyst, "hope" is not a risk management strategy. You need a data-driven framework to identify the exact institutional "buy-zones" and the immediate invalidation points before the next markdown phase begins. Inquire via the WhatsApp link in my bio for the specific operation strategy and the daily invalidation levels for $OCGN.

@NattaCop Are we worried about the inverse between the medium dose and high dose? Efficacy is overall good and 46 percent reduction but just curious? Apparently it’s not good?

$ocgn OCU410 analysis and US revenue projections. Most won’t realize how conservative this really is. 🍻

@waelti_capital Sooo a higher support than $1.90? Not familiar with Elliot wave so which is why I am asking?

It may act as support, but I don’t think it would hold against an ABC correction. If Ocugen develops an extended wave 5, the support could become stronger. #ocugen #BullRun #Elliottwave

@waelti_capital Do you see $1.90 becoming support after wave 5 is over or dipping back down into the channel?

In my last post, I mentioned the level that would need to be sustainably broken to invalidate the bullish scenario. That didn’t happen, Ocugen is now on a solid path to complete Wave 5. #Ocugen #stockmarkets #elliotwave

@MoreFlax @Ocugen @drsmusunuri Question how long or what is needed to get one??

$OCGN #OCUGEN @Ocugen @drsmusunuri 👇 ♥️ ❤️ 😍

@waelti_market Aye dawg I need an update here😂 where’s the 5th wave start or what’s our future outlook. Did your scenario not work out?

@troypeaches At the moment yes, it depends where the smaller wave 4 ends

Ocugen jumped 20% today with highly impulsive moves. The chance of an extended wave is rising, along with higher minimum targets. Elliott Wave analysis shows nearly 50% gains through the target zone and this could be just the start of something bigger. #Ocugen #Bullish #Stocks

@MoreFlax I don’t see a partnership happening to fund ocu400. Hope I am wrong. Should still rise but not to where we want it if they keep diluting. Maybe a partner for ocu410ST.

$OCGN #OCUGEN 👇 👇 👇 So, just bringing this as a factual statement, the recent offering was filed under its shelf registration statement which was filed with SEC in 2024. If I can remind you it was $175 mill in total, which might be tapped in at any time.

@VishalDattani8 4 playoff comebacks is buckling under pressure? You are slow.

#49ers #purdy must go! Not elite at all. Buckles under pressure

@waelti_market What’s your opinion? We still have a good out look to break $1.90 again?

@troypeaches No problem. Even if an extended fifth wave occurs, the past action would be counted the same way. It would only mean that wave 5 could extend to 1.618 times the length of the previous two waves.

@NattaCop Help me out here. Didn’t the merger of orthocellix and charisma fall through? Orthocellix is a subsidiary of ocugen correct?

$ocgn 😜

@Emeraldphilipp Looking at this it’s hard to see this running to $150 in the next two years and then revisiting $21? Big wav correction no?

@Emeraldphilipp lol if this happens that would be sick.

$OCGN #Ocugen #elliot Elliot Wave Analysis, highly appreciate feedback and direct opinions

@waelti_market Little nervous here in this. $1.80 in after hours lol. On the money. I feel like this could keep rockin.

@troypeaches I agree, Wave 3 should at least reach $1.80. Otherwise, the Elliott Wave count would be invalid, since Wave 3 cannot be the shortest. Alternatively an extended Wave 3 or 5 is possible, but it’s still too early to favor that scenario.

Ocugen update: Ocugen is looking very strong for a 5-wave structure. Wave 1 on a lower degree appears to be complete, and Wave 3 may now be starting. A move above 1.90 would be the minimum needed to clearly confirm the formation of Wave 5. #Ocugen #Stocks #BullMarket

@BASportsDude Sigle was doing well against the run too.

@troypeaches Ya brown and mustapha are basically in the box style safeties with zero ability to create turnovers. Pinnock or Sigle deserve a chance.

#49ers D better without Brown playing?

Tired of seeing defense comments. We are down to 3rd string and couch type playing LBs literally. You know what the D is…. Offense needs to keep us in and Philly needs to screw up. #49ers

Our linebackers just collided…. Come on guys#49ers